LAKE FOREST, Ill., May 20, 2011 /PRNewswire/ — Hospira, Inc. (NYSE:
HSP), a leading provider of clinical information and medication
delivery technologies, today announced that the company has
received regulatory approval from Health Canada for its software
upgrade to the Symbiq™
infusion system. As a result, Hospira has resumed shipments of
Symbiq pumps in Canada and is working with current customers in the
region to upgrade to the new version of the software.
“With the upgraded Symbiq infusion system, our goal is to
provide hospitals with one of the most advanced and highest quality
infusion pumps available today,” said Gerry Stefanatos, vice
president, Canada and Latin America, Hospira. “This regulatory
approval is a testament to the work we’ve done to help ensure the
robustness, dependability and flexibility of the Symbiq device. We
are now focused on partnering with hospital customers in Canada who
are ready to have their current Symbiq system upgraded and new
infusion pumps implemented.”
The upgraded Symbiq software includes modifications to further
ensure the reliability of the device. During the Symbiq
modification process, Hospira:
- enhanced the operational performance of the infusion pump to
reflect customer feedback and address recent device field
corrections, - improved the device software to perform consistently across
varying infusion pump clinical practices, and - reevaluated the software design to ensure optimal operation
within the product specifications.
The Symbiq infusion system is a technologically advanced
infusion pump with several clinician-friendly features incorporated
to help improve workflow and decrease medication errors. For
example, the Symbi
‘/>”/>
